DBV Technologies

The biotech resurrection continues
The biotech resurrection continues
EP Vantage
biotech
Lexicon Pharmaceuticals
DBV Technologies
Pfizer
Trillium Therapeutics
Flag link:
DBV restructuring claims 200 jobs as it beats out a path toward peanut patch OK
DBV restructuring claims 200 jobs as it beats out a path toward peanut patch OK
Endpoints
DBV Technologies
peanut allergy
Viaskin Peanut
layoffs
Flag link:
Why DBV Technologies Stock Is Soaring Today
Why DBV Technologies Stock Is Soaring Today
Motley Fool
DBV Technologies
Viaskin Peanut
peanut allergy
Europe
EMA
Flag link:
Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them
Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them
BioSpace
DBV Technologies
Viaskin Peanut
peanut allergy
FDA
Flag link:
FDA turns back DBV Technologies’ peanut allergy patch, raising questions about its design
FDA turns back DBV Technologies’ peanut allergy patch, raising questions about its design
Fierce Biotech
DBV Technologies
FDA
Viaskin Peanut
Flag link:
With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash
With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash
Xconomy
DBV Technologies
FDA
peanut allergy
layoffs
Viaskin Peanut
Flag link:
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
Motley Fool
peanut allergy
Viaskin Peanut
DBV Technologies
Aimmune Therapeutics
Palforzia
Flag link:
In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions
In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions
Endpoints
FDA
Aimmune
DBV Technologies
peanut allergy
Viaskin Peanut
Flag link:
DBV's peanut prevention patch approaches key stage of approval process
DBV's peanut prevention patch approaches key stage of approval process
Endpoints
DBV Technologies
peanut allergy
FDA
drug approvals
Viaskin Peanut
Flag link:
What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline
What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline
Motley Fool
Aimmune
FDA
peanut allergy
Palfozia
DBV Technologies
Flag link:
FDA decision nears on Aimmune's contested peanut allergy drug
FDA decision nears on Aimmune's contested peanut allergy drug
BioPharma Dive
FDA
Aimmune
peanut allergy
Palforzia
DBV Technologies
Viaskin Peanut
Flag link:
DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy
DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy
Pharmaceutical Business Review
Viaskin Peanut
DBV Technologies
FDA
peanut allergy
Flag link:
DBV Technologies Resubmits BLA for Peanut Allergy Treatment
DBV Technologies Resubmits BLA for Peanut Allergy Treatment
BioSpace
DBV Technologies
FDA
peanut allergy
Viaskin Peanut
Flag link:
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
Endpoints
peanut allergy
Aimmune Therapeutics
DBV Technologies
ICER
AR101
Viaskin Peanut
Flag link:
DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead
DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead
Xconomy
DBV Technologies
Aimmune
peanut allergy
AR-101
Viaskin Peanut
Flag link:
DBV Technologies pulls peanut allergy treatment from FDA review
DBV Technologies pulls peanut allergy treatment from FDA review
Stat
DBV Technologies
peanut allergy
FDA
Viaskin Peanut
Flag link:
DBV climbs as messy milk allergy data open door to phase 3
DBV climbs as messy milk allergy data open door to phase 3
Fierce Biotech
DBV Technologies
food allergies
milk allergy
Viaskin Milk
Flag link:
DBV climbs as peanut allergy safety data come in clean
DBV climbs as peanut allergy safety data come in clean
Fierce Biotech
peanut allergy
DBV Technologies
Viaskin Peanut
Flag link:
A new peanut allergy vaccine failed in a trial, but the company wants it approved anyway
A new peanut allergy vaccine failed in a trial, but the company wants it approved anyway
Stat
vaccines
food allergies
peanut allergy
DBV Technologies
Viaskin Peanut
Flag link:
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Flag link:

Pages